论文部分内容阅读
基因表达分析系统和预后因子的组合能更正确预测恶性淋巴瘤的预后。利妥昔单抗(rituximab)联合化疗可大幅提高B细胞淋巴瘤的治疗效果,本文进一步探讨了应用利妥昔单抗行首次治疗时的预后预测因子和最佳的补救治疗方法。放射免疫疗法(radioimmu-notherapy)在滤泡型淋巴瘤的初次治疗、复发难治性B细胞性淋巴瘤的补救治疗、自身移植前期处理的应用中均显示了安全性和有效性。报道了分子靶向疗法和特异型免疫球蛋白为抗原的免疫疗法的第Ⅰ/Ⅱ期试验,并期待这种新型治疗的发展。
The combination of gene expression analysis system and prognostic factor can predict the prognosis of malignant lymphoma more correctly. Rituximab (rituximab) combined with chemotherapy can significantly improve the treatment of B-cell lymphoma, the paper further explore the use of rituximab in the first treatment prognosis predictors and the best remedial treatment. Radioimmunotherapy (radioimmu-notherapy) has shown safety and efficacy in the initial treatment of follicular lymphoma, the remediation of relapsed and refractory B-cell lymphoma, and the application of pre-transplant treatment. A Phase I / II trial of molecular targeted therapy and immunotherapy with specific immunoglobulins as antigens has been reported and the development of this new type of therapy is expected.